The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

enoxbiopharma.com

Founded Year

2007

About Enox Biopharma

Enox Biopharma is a biotechnology company that developed a drug eluting technology suitable for treatment of acute and antibiotic resistant ear infection in children.

Enox Biopharma Headquarter Location

27 Havradim Street

56275,

Israel

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Enox Biopharma Patents

Enox Biopharma has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/19/2008

10/25/2011

Auditory system, Ear, Audiology, Otorhinolaryngology, Implants (medicine)

Grant

Application Date

9/19/2008

Grant Date

10/25/2011

Title

Related Topics

Auditory system, Ear, Audiology, Otorhinolaryngology, Implants (medicine)

Status

Grant

  • When was Enox Biopharma founded?

    Enox Biopharma was founded in 2007.

  • Who are Enox Biopharma's competitors?

    Competitors of Enox Biopharma include Array Biopharma, Endocyte, Cellerant Therapeutics, Asmacure, ACT Biotech and 12 more.

You May Also Like

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

T
Timi3 Systems

Timi3 Systems, Inc., a biotechnology company, develops a non-invasive transcutaneous ultrasound system for the treatment of patients experiencing an acute myocardial infarction or heart attack. The company specializes in the non-invasive delivery of thrombolytic drugs that hasten the dissolution of thrombus during a myocardial infarction. Timi3 Systems, Inc. was founded in 1999 and is based in Santa Clara, California.

Cellerant Therapeutics Logo
Cellerant Therapeutics

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.

D
Dialectica srl

Dialectica offers Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases. The mission of Dialectica is to add value to the link between research and pharmaceutical and biotechnology companies that are active in the discovery of therapeutics for brain diseases. Dialectica develops and optimize Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases.

S
Stem Cells Bank

Stem Cells Bank Biotechnological Company engaged in development of autovaccines for treating oncological diseases and tuberculosis, produced on the basis of autologous dendritic cells (cells extracted from the organism of the very patient to be given the vaccine). In the framework of thus project it is planned to develop and launch a vaccine for treating oncological diseases and tuberculosis, produced on the basis of cells extracted from the organism of the very patient to be given the vaccine.

Longevica Logo
Longevica

Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.